跳到正文
营养与代谢随机试验荟萃分析3 分钟阅读

糖尿病自我管理应用与糖化血红蛋白降低0.48%相关:12项试验汇总

MoveVitals 编辑部 · 研究发表 · 解读更新

原文:Mobile App-Based Interventions to Support Diabetes Self-Management: A Systematic Review of Randomized Controlled Trials to Identify Functions Associated with Glycemic Efficacy. · JMIR mHealth and uHealth · 2017 · 论文原文 ↗

先看重点

汇总12项随机对照试验、共974名成年糖尿病患者,与单纯常规治疗相比,应用干预使糖化血红蛋白(HbA1c)降低0.48%(95%置信区间0.19%至0.77%),且未增加不良事件。不同功能的比较属探索性亚组分析,涉及试验很少,只能提示假设,不能证明哪种设计更好。

证据类型

随机试验荟萃分析

解读依据

公开摘要

阅读重点

方法与适用范围

研究在问什么

糖尿病应用的功能差别很大,此前既没有统一的分类方法,也不清楚哪些功能对血糖有帮助。研究者先建立了应用功能分类,再检验应用能把糖化血红蛋白降低多少,以及哪些功能与更大的降幅相关。

研究了谁,如何研究

这是一项系统综述,采用随机效应模型做荟萃分析。研究者先建立了三轴分类(临床模块、功能模块、带风险评估的具体功能),并通过归类市售糖尿病应用进行验证。随后检索MEDLINE、EMBASE、Cochrane对照试验中心注册库、中国生物医学文献数据库和ClinicalTrials.gov中2007年1月至2016年5月的文献,纳入比较应用干预与单纯常规治疗、受试者为成年糖尿病门诊患者的随机对照试验。汇总糖化血红蛋白的均数差和不良事件的风险比,并按各模块有无做探索性亚组分析。

主要发现

以下为作者报告的结果。数字须连同人群和不确定性一起阅读。

  1. 1
    12项试验共974名参与者,应用干预与糖化血红蛋白降低0.48%相关(95%置信区间0.19%至0.77%),未增加不良事件。
  2. 2
    2型糖尿病患者的降幅(0.67%,95%置信区间0.30%至1.03%)大于1型糖尿病患者(0.36%,95%置信区间0.08%至0.81%)。
  3. 3
    带并发症预防模块的应用降幅更大(1.31%,95%置信区间0.66%至1.96%),不带该模块者为0.38%(95%置信区间0.09%至0.67%;亚组间P=.01)。结构化数据展示也与更大降幅相关(0.69%对0.16%;P=.03)。
  4. 4
    临床决策功能与更大降幅无关(有该功能为0.18%,无为0.61%;P=.10)。

局限与不确定性

  1. 1
    仅12项试验,每个亚组比较只依赖少数研究,不少置信区间很宽。
  2. 2
    模块比较是探索性的,也不是随机分配;带某模块的应用往往在其他方面也不同,因此不一定是该模块起作用。
  3. 3
    摘要中个别区间与点估计看起来不一致(例如0.16%的区间下限也是0.16%),亚组数字需谨慎解读。
  4. 4
    本解读仅基于摘要;试验质量、随访时长和异质性未报告。

对日常健康的启示

平均而言,在常规治疗之外使用应用,糖化血红蛋白有小幅下降,在2型糖尿病中信号更强。这一结果无法告诉你该选哪款应用,也不意味着应用可以代替诊疗;调整任何管理方式前,应与你的糖尿病诊疗团队商量。

如何联系自己的数据

如果你在应用中记录血糖、饮食或用药,真正有用的比较是自己数月内的糖化血红蛋白或血糖趋势,并使用同一血糖仪或连续血糖监测设备、相近的测量条件。单次读数波动太大,不足以评价一款应用。

如何理解这类证据

合并试验可提高精度,但人群、对照、偏倚与不确定性仍重要;网络排名包含间接证据,不是通用最佳方案。

作者的结构化摘要 English

以下英文摘要按记录的开放许可转载,属于作者原始材料,不是 MoveVitals 的解读。上方已提供研究解读,分别说明作者结果与本站解释;重要结论可直接核对原文。

Background

Mobile health apps for diabetes self-management have different functions. However, the efficacy and safety of each function are not well studied, and no classification is available for these functions.

Objective

The aims of this study were to (1) develop and validate a taxonomy of apps for diabetes self-management, (2) investigate the glycemic efficacy of mobile app-based interventions among adults with diabetes in a systematic review of randomized controlled trials (RCTs), and (3) explore the contribution of different function to the effectiveness of entire app-based interventions using the taxonomy.

Methods

We developed a 3-axis taxonomy with columns of clinical modules, rows of functional modules and cells of functions with risk assessments. This taxonomy was validated by reviewing and classifying commercially available diabetes apps. We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, the Chinese Biomedical Literature Database, and ClinicalTrials.gov from January 2007 to May 2016. We included RCTs of adult outpatients with diabetes that compared using mobile app-based interventions with usual care alone. The mean differences (MDs) in hemoglobin A_(1c) (HbA_(1c)) concentrations and risk ratios of adverse events were pooled using a random-effects meta-analysis. After taxonomic classification, we performed exploratory subgroup analyses of the presence or absence of each module across the included app-based interventions.

Results

Across 12 included trials involving 974 participants, using app-based interventions was associated with a clinically significant reduction of HbA_(1c) (MD 0.48%, 95% CI 0.19%-0.77%) without excess adverse events. Larger HbA_(1c) reductions were noted among patients with type 2 diabetes than those with type 1 diabetes (MD 0.67%, 95% CI 0.30%-1.03% vs MD 0.36%, 95% CI 0.08%-0.81%). Having a complication prevention module in app-based interventions was associated with a greater HbA_(1c) reduction (with complication prevention: MD 1.31%, 95% CI 0.66%-1.96% vs without: MD 0.38%, 95% CI 0.09%-0.67%; intersubgroup P=.01), as was having a structured display (with structured display: MD 0.69%, 95% CI 0.32%-1.06% vs without: MD 0.16%, 95% CI 0.16%-0.48%; intersubgroup P=.03). However, having a clinical decision-making function was not associated with a larger HbA_(1c) reduction (with clinical decision making: MD 0.18%, 95% CI 0.21%-0.56% vs without: MD 0.61%, 95% CI 0.27%-0.95%; intersubgroup P=.10).

Conclusions

The use of mobile app-based interventions yields a clinically significant HbA_(1c) reduction among adult outpatients with diabetes, especially among those with type 2 diabetes. Our study suggests that the clinical decision-making function needs further improvement and evaluation before being added to apps.

来源与署名

Mobile App-Based Interventions to Support Diabetes Self-Management: A Systematic Review of Randomized Controlled Trials to Identify Functions Associated with Glycemic Efficacy.

Wu Y, Yao X, Vespasiani G, Nicolucci A, Dong Y, Kwong J, Li L, Sun X, Tian H, Li S.

JMIR mHealth and uHealth · 2017-03-14

DOI: 10.2196/mhealth.6522 ↗PubMed · 28292740 ↗Europe PMC · 记录的开放许可: cc by ↗

摘要版权归原作者,依据来源记录的开放许可转载。中文译文辅助阅读,英文摘要用于核对术语与具体数值;本站的方法学解释与作者结论分别呈现。

MoveVitals 编辑解读 · 健康教育内容 · 未记录个人临床审阅

来源核验日期 2026-11-01

实用健康指南

放在一起读

·随机试验荟萃分析

更早的进食窗口与更大的体重和胰岛素获益相关,优于晚间进食

汇总41项随机对照试验(2287名参与者,干预时间中位数8周)发现,限时进食比日常饮食体重低2.15 kg(95%置信区间−2.56至−1.74),而早吃比晚吃体重多降1.15 kg(95%置信区间−1.86至−0.45)。多数试验较短,只有6个研究组检验了早间进食,结局是身体和血液指标,不是心脏病发作或死亡。

BMJ Medicine

重点论文精讲阅读论文 →
·随机对照试验

限热量饮食再加上午8点至下午4点进食窗口,1年减重无明显额外优势

139名肥胖患者都按限制热量的饮食进食,其中一组再加上上午8:00至下午4:00的进食窗口,12个月平均体重变化为−8.0 kg,单纯限热量组为−6.3 kg。净差值−1.8 kg(95%置信区间−4.0至0.4;P=0.11)无统计学意义,该区间既不能排除窗口确有获益,也不能排除毫无作用。

The New England Journal of Medicine

重点论文精讲阅读论文 →
·随机对照试验

20人住院试验:超加工饮食让人每天多摄入508 kcal并增重

20名成年人在医院研究病房住了28天,两种菜单各吃2周、想吃多少吃多少:超加工菜单让他们每天多摄入508 kcal(±106,标准误,P=0.0001),体重增加0.9 kg;未加工菜单则让体重减轻0.9 kg。样本小、周期短、食物全程由研究方提供,既不能说明日常生活中的长期结果,也无法确定是食物的哪种特点导致多吃。

Cell Metabolism

重点论文精讲阅读论文 →
·随机对照试验

地中海饮食加橄榄油或坚果与心血管事件减少相关(更正后的试验)

在7447名55至80岁、心血管风险较高的西班牙成年人中,被分到加特级初榨橄榄油(风险比0.69,95%置信区间0.53至0.91)或加坚果(风险比0.72,0.54至0.95)的地中海饮食组,发生主要心血管事件的风险低于被告知减少脂肪的对照组。试验存在随机化失误,2013年的报告已撤回并重新估算,证据有力但并不完美。

The New England Journal of Medicine

重点论文精讲阅读论文 →
营养与代谢 →